Mitsui to close several Japanese plants and expand in China


Japanese firm Mitsui Chemicals is planning to shut down operations at several sites, while expanding others in an effort to become more profitable. The company is moving away from commodity isocyanate and phenolic chemicals that are currently oversupplied in Asia, and concentrating on xylene diisocyanate (XDI) and other specialities for which it is the main supplier. It is also aiming to decrease exports to China, which have been devalued by the weakness of the Yen, and establish new production plants in China to compete in the growing local market.

Mitsui will completely close its Kashima works, as well as the phenol and bisphenol A plants owned by its Chiba Phenol joint venture with Idemitsu Kosan. Mitsui will also cease its Japanese production of diphenylmethane diisocyanate (MDI) at Omuta, and convert that site to produce larger volumes of speciality isocyanates including XDI. The company will continue to produce toluene diisocyanate (TDI) at Omuta, and MDI through its Korean subsidiary.

To combat the high export duties and transport costs of shipping phenols from Japan to China, Mitsui intends to build a large scale phenols plant in China to compete in the local market, in partnership with Chinese chemicals giant Sinopec.


Related Content

Booms and bust-ups

9 January 2015 Business

news image

Chemicals industry roundup 2014

Chemistry in bloom

23 September 2014 Feature

news image

Sarah Houlton discovers the chemistry among the specimens at many botanical gardens

Most Read

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Chemists zinc up ‘aromatic’ metal cubes

2 March 2015 Research

news image

Metal-organic clusters share electrons between eight covalently linked metal atoms

Most Commented

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Hepatitis C drug patent challenged in Europe

19 February 2015 Business

news image

Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent